Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Cardiol Therapeutics Inc Class A
CT9Current price
1.19 EUR
-0.002 EUR (-0.17%)
Last closed
1.83 CAD
Company
www.cardiolrx.com
ISIN
CA14161Y2006
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
Frankfurt Exchange
Capitalization
156 108 063 CAD
Yield for 12 month
+28.78 %
1Y
3Y
5Y
10Y
15Y
CT9
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada. Address: 2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
15.79 CADP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-249 399 CAD
Last Year
-220 832 CAD
Current Quarter
-62 168 CAD
Last Quarter
-61 883 CAD
Key Figures CT9
1 year
3 years
5 years
10 years
EBITDA
-31 794 560 CAD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-54.15 %
PEG Ratio
–
Return On Equity TTM
-108.44 %
Wall Street Target Price
15.79 CAD
Revenue TTM
–
Book Value
0.43 CAD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
79 091 CAD
Earnings per share
-0.54 CAD
Diluted Eps TTM
-0.54 CAD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics CT9
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History CT9
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation CT9
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
230.52
Price Sales TTM
1 273.79
Enterprise Value EBITDA
0.41
Price Book MRQ
14.90
Financials CT9
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators CT9
For 52 weeks
1.07 CAD
4.28 CAD
50 Day MA
2.45 CAD
Shares Short Prior Month
345 858
200 Day MA
2.70 CAD
Short Ratio
2.22
Shares Short
263 207
Short Percent
0.34 %
BeatStart